Novo Nordisk A/S – Share repurchase programme

BAGSVAERD, DENMARK--(Marketwired - May 21, 2013) - On 3 May 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273…

---

Novo Nordisk reports positive results from Phase-3 haemophilia B study of N9-GP

Novo Nordisk has reported positive results from Phase-3 study of FIX derivative N9-GP to treat haemophilia B.

---

Novo Nordisk completes PhIII hemophilia trial with positive results

In a Friday announcement, Novo Nordisk said it completed the first phase III trial of its drug N9-GP for hemophilia B patients.

---

Novo Nordisk says completes hemophilia drug trial

COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP.

---